BR112015022514A2 - composições que compreendem selênio e uso das mesmas para o tratamento e prevenção de doença ou condições associadas à disfunção mitocondrial - Google Patents

composições que compreendem selênio e uso das mesmas para o tratamento e prevenção de doença ou condições associadas à disfunção mitocondrial

Info

Publication number
BR112015022514A2
BR112015022514A2 BR112015022514A BR112015022514A BR112015022514A2 BR 112015022514 A2 BR112015022514 A2 BR 112015022514A2 BR 112015022514 A BR112015022514 A BR 112015022514A BR 112015022514 A BR112015022514 A BR 112015022514A BR 112015022514 A2 BR112015022514 A2 BR 112015022514A2
Authority
BR
Brazil
Prior art keywords
selenium
compositions
enriched yeast
diabetes
methods
Prior art date
Application number
BR112015022514A
Other languages
English (en)
Inventor
Yiannikouris Alexandros
Egan Casey
Collen Jackson Lewis
Xiao Rijin
Power Ronan
Kwiatkowski Stefan
Lan Zi-Jian
Original Assignee
Alltech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alltech Inc filed Critical Alltech Inc
Publication of BR112015022514A2 publication Critical patent/BR112015022514A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Abstract

abstract the present application relates to compositions comprising selenium (e.g., selenium enriched yeast and selenium containing compounds obtained or derived therefrom) and methods of using the same to treat and inhibit obesity, diabetes and related conditions. in particular, the present application provides compositions comprising selenium enriched yeast (e.g., selenium enriched yeast comprising 2% or less inorganic selenium), selenium containing compounds present therein and/or derived therefrom, and methods of using the same to enhance mitochondrial activity and function (e.g., in skeletal muscle and liver) in a subject (e.g., as a therapeutic and/or prophylactic treatment for diabetes, obesity and related conditions). tradução do resumo resumo patente de invenção: "composições que compreendem selênio e uso das mesmas para o tratamento e prevenção de doença ou condições associadas à disfunção mitocondrial" a presente invenção se refere a composições que compreendem selênio (por exemplo, levedura enriquecida com selênio e compostos que contêm selênio obtidos ou derivados dos mesmos) e métodos para usar as mesmas para tratar e inibir a obesidade, diabetes e condições relacionadas. em particular, a presente aplicação fornece composições que compreendem levedura enriquecida com selênio (por exemplo, levedura enriquecida com selênio que compreende 2% ou menos de selênio inorgânico), compostos que contêm selênio presentes nos mesmos e/ou derivados dos mesmos e métodos para usar os mesmos para aprimorar atividade e função mitocondrial (por exemplo, em músculo esquelético e fígado) em um indivíduo (por exemplo, como um tratamento terapêutico e/ou profilático para diabetes, obesidade e condições relacionadas). 1/1
BR112015022514A 2013-03-15 2014-03-14 composições que compreendem selênio e uso das mesmas para o tratamento e prevenção de doença ou condições associadas à disfunção mitocondrial BR112015022514A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361788133P 2013-03-15 2013-03-15
PCT/US2014/029328 WO2014144776A1 (en) 2013-03-15 2014-03-14 Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction

Publications (1)

Publication Number Publication Date
BR112015022514A2 true BR112015022514A2 (pt) 2017-07-18

Family

ID=51537786

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015022514A BR112015022514A2 (pt) 2013-03-15 2014-03-14 composições que compreendem selênio e uso das mesmas para o tratamento e prevenção de doença ou condições associadas à disfunção mitocondrial

Country Status (15)

Country Link
US (1) US9833486B2 (pt)
EP (1) EP2968404A4 (pt)
JP (1) JP6313418B2 (pt)
KR (1) KR102245702B1 (pt)
CN (3) CN114984038A (pt)
AU (1) AU2014228785B2 (pt)
BR (1) BR112015022514A2 (pt)
CA (1) CA2903845C (pt)
CL (1) CL2015002677A1 (pt)
HK (1) HK1216506A1 (pt)
MX (1) MX359626B (pt)
RU (1) RU2663127C2 (pt)
SG (2) SG10202101918RA (pt)
WO (1) WO2014144776A1 (pt)
ZA (1) ZA201506759B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014236559B2 (en) 2013-03-14 2020-03-12 Julie HUGHES Cholestosome vesicles for incorporation of molecules into chylomicrons
CA2940283C (en) * 2014-03-14 2021-03-30 Alltech, Inc. Compositions of selenoorganic compounds and methods of use thereof
EP3273972A4 (en) 2015-03-27 2018-10-31 The Research Foundation for The State University of New York Methods and materials for reducing amyloid beta levels within a mammal
WO2017048252A1 (en) * 2015-09-15 2017-03-23 Alltech, Inc. Compositions of selenoorganic compounds and methods of use thereof
WO2017160678A1 (en) * 2016-03-14 2017-09-21 Mitogenetics, Llc Materials and methods for treating hypoxic conditions
US11014954B2 (en) 2017-05-19 2021-05-25 Alltech, Inc. Pharmaceutical agents, compositions, and methods relating thereto
CN108283711A (zh) * 2018-05-06 2018-07-17 冷立娟 一种治疗酒精性心肌病的中药冲剂及其制备方法
CN109820933A (zh) * 2019-02-27 2019-05-31 北京曲佳科技有限公司 减肥片及其制备方法
CN111493325A (zh) * 2020-05-07 2020-08-07 恩施德源健康科技发展有限公司 植物硒肽在制备改善肥胖及代谢综合征组合物中的应用
CN112129864B (zh) * 2020-09-24 2022-04-01 江南大学 一种富硒植物干粉中硒形态测定的方法
KR102328808B1 (ko) * 2020-12-02 2021-11-22 동의대학교 산학협력단 맥주효모를 이용한 근감소증 예방 및 개선용 조성물
CN114053298A (zh) * 2021-11-19 2022-02-18 华中农业大学 一种用于抑制心肌肥大的药物及模型的构建方法
CN114235989A (zh) * 2021-11-27 2022-03-25 山东省烟台市农业科学研究院 一种测定福美甲胂含量的高效液相色谱法
CN114031650B (zh) * 2021-11-29 2023-05-02 上海交通大学 壳寡糖硒配位化合物及其制备方法和应用
CN114931569B (zh) * 2022-06-22 2023-05-16 中国农业科学院油料作物研究所 甲基硒代半胱氨酸在制备提高雄性生殖能力的产品中的应用
CN116333302A (zh) * 2023-03-31 2023-06-27 中南大学 一种稳定持久抗氧化纳米点及其在二型糖尿病中的应用
CN116421618B (zh) * 2023-06-15 2023-09-29 暨南大学 Se@NADH的制备方法及其在脊髓损伤治疗中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5896024A (ja) * 1981-10-16 1983-06-07 リチヤ−ド・エフ・ストツケル 白金毒解毒剤
WO2004107881A1 (en) * 2003-06-04 2004-12-16 Serfontein, Willem, Jacob Nutritional compositions and use thereof
PL214402B1 (pl) * 2003-08-11 2013-07-31 Tomasz Byrski Zastosowanie selenu albo jego zwiazku do otrzymywania srodka do obnizania odziedziczonego ryzyka zachorowania na raka piersi lub jajnika
US20070026090A1 (en) * 2003-09-05 2007-02-01 Oren Tirosh Treatment and prevention of inflammatory disease and mitochondrial dysfunction with high dose selenium
CN102764279B (zh) * 2005-10-14 2015-04-01 全面技术公司 改变细胞功能的方法和组合物
US8871715B2 (en) * 2005-10-14 2014-10-28 Alltech, Inc. Use of selenium compounds, especially selenium yeasts for altering cognitive function
US20100247679A1 (en) 2006-04-24 2010-09-30 Alltech, Inc. Methods and compositions for altering cell function
WO2008144543A2 (en) * 2007-05-18 2008-11-27 Alltech, Inc. Compositions and methods for establishing and/or maintaining pregnancy
NZ583025A (en) 2007-07-31 2012-06-29 Univ Texas Micro-rnas that control myosin expression and myofiber identity
US8796241B2 (en) * 2007-08-29 2014-08-05 Adam Lubin Therapy of tumors and infectious agents deficient in methylthioadenosine phosphorylase
NZ585280A (en) * 2007-10-16 2011-05-27 Exichol Sa Composition for regulating lipid metabolism
CN101579355B (zh) * 2009-05-27 2010-12-08 徐建兴 一种维护线粒体功能的营养组合物及其应用
NZ599996A (en) * 2009-10-22 2014-06-27 Propanc Pty Ltd A pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent
JP5896421B2 (ja) * 2010-04-22 2016-03-30 国立大学法人京都大学 多能性幹細胞から骨格筋または骨格筋前駆細胞への分化誘導法
KR20120048205A (ko) * 2010-11-05 2012-05-15 한국식품연구원 메틸셀레노시스테인을 유효성분으로 함유하는 비만 및 지질 관련 대사성 질환의 예방 및 치료용 조성물
KR102100091B1 (ko) 2011-04-13 2020-04-14 아지노모토 가부시키가이샤 영양 조성물

Also Published As

Publication number Publication date
SG10202101918RA (en) 2021-03-30
CN114533753A (zh) 2022-05-27
KR102245702B1 (ko) 2021-04-28
CN105377271A (zh) 2016-03-02
KR20150132374A (ko) 2015-11-25
RU2015139742A (ru) 2017-04-21
MX2015013275A (es) 2015-12-11
JP2016516058A (ja) 2016-06-02
RU2663127C2 (ru) 2018-08-01
CN114984038A (zh) 2022-09-02
SG11201507061XA (en) 2015-10-29
JP6313418B2 (ja) 2018-04-18
WO2014144776A1 (en) 2014-09-18
MX359626B (es) 2018-10-01
US9833486B2 (en) 2017-12-05
EP2968404A1 (en) 2016-01-20
AU2014228785A1 (en) 2015-09-24
CA2903845A1 (en) 2014-09-18
CA2903845C (en) 2022-08-23
EP2968404A4 (en) 2017-01-04
US20160113977A1 (en) 2016-04-28
ZA201506759B (en) 2017-03-29
NZ711842A (en) 2021-04-30
HK1216506A1 (zh) 2016-11-18
CL2015002677A1 (es) 2016-12-09
AU2014228785B2 (en) 2018-01-25

Similar Documents

Publication Publication Date Title
BR112015022514A2 (pt) composições que compreendem selênio e uso das mesmas para o tratamento e prevenção de doença ou condições associadas à disfunção mitocondrial
BR112015008447A2 (pt) métodos para tratar câncer
EA201800367A1 (ru) Способы лечения болезни хантингтона
BR112015014458A2 (pt) derivados de manose para o tratamento de infecções bacterianas
BR112017012327A2 (pt) benzamidas substituídas por 1,3-tiazol-2-il.
BR112015011403A2 (pt) uso de akkermansia para o tratamento de distúrbios metabólicos
BR112017026739A2 (pt) compostos para uso no tratamento de distúrbios neuromusculares
BR112016014481A2 (pt) tratamento de câncer utilizando combinações de inibidores de erk e raf
BR112016013734A2 (pt) Composto, composição farmacêutica, kit, e uso de um composto
EA201591743A1 (ru) СТИМУЛЯТОРЫ sGC
BR112015023922A2 (pt) composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes
BR112015022197A8 (pt) uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia
BRPI0611717A2 (pt) composto, composiÇço farmacÊutica e uso do composto
BR112012004806B8 (pt) composições imunogênicas que incluem moduladores da atividade de tlr, método para aumento da eficácia da referida composição e uso
BR112013010021A2 (pt) combinações farmacêuticas para o tratamento de distúrbios metabólicos.
BR112015024846A2 (pt) composições para utilização no estímulo do crescimento ósseo
BR112016013109A2 (pt) anticorpos de anti-siglec-8 e métodos de seu uso
BR112014016810A2 (pt) composições e métodos para tratamento de distúrbios metabólicos
BR112013018782A2 (pt) compostos e seus efeitos no comportamento alimentar
BR112018006368A2 (pt) composição para desempenho melhorado
BR112014006587A8 (pt) Composto compreendendo oligonucleotídeo que modula a expressão de gcgr, composição, bem como seu uso no tratamento ou prevenção de diabetes
BR112015026247A8 (pt) composto em combinação com um análogo de citidina, composição farmacêutica que os compreende, uso dos mesmos e kit
BR112014019399A2 (pt) métodos de tratamento da fibrose
BR112012032721A2 (pt) compostos heterocíclicos, sua preparação e sua aplicação terapêutica
BR112015022982A2 (pt) inibidores macrocíclicos de rip2 quinase

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25G Requested change of headquarter approved

Owner name: ALLTECH, INC. (US)

B25C Requirement related to requested transfer of rights

Owner name: ALLTECH, INC. (US)

Free format text: A FIM DE ATENDER AS ANOTACOES DE LIMITACAO OU ONUS REQUERIDAS E NECESSARIO ESCLARECER A DIVERGENCIA ENTRE O ATUAL DEPOSITANTE ?ALLTECH, INC.? E O CONSTANTE NOS DOCUMENTOS DE LIMITACAO APRESENTADOS ?ALLTECH DO BRASIL AGROINDUSTRIAL LTDA.?, POIS, NOS DOCUMENTOS APRESENTADOS, QUEM SOFREU A LIMITACAO OU ONUS FOI ?ALLTECH DO BRASIL AGROINDUSTRIAL LTDA.? E O ATUAL DEPOSITANTE E ?ALLTECH, INC.?.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]